© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
ClonoSEQ assay tests for minimal residual disease, or very low levels of cancer cells in bone marrow.
The new therapies include immune checkpoint inhibitors; therapeutic vaccines; CAR T-cell therapies; and “conjugate” drugs.
Approval extended to people who are in remission but have minimal residual disease.
Coming up at AACR: Chemotherapy can compromise CAR-T therapy and HER2 mutations may confer resistance to hormone therapy.
Immunotherapy that targets two different receptors on tumors may help prevent relapse.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
